MKI67 and neoplasm: Among C responders, we also compared K responders versus K non-responders (C+K+  vs C+K−) and noted enrichment in immune pathways in C+K+ tumours, in addition to pathways found between K+ versus K− patients, indicating that there is greater enrichment in immune genes among clinical responders in tumours that have a robust Ki67 response to trastuzumab versus K-unresponsive cases (Figure S1).